litlas
Log inCreate account

David M. Goldenberg

Active 1966–2024

161
Papers
25,955
Citations
103
h-index
160
i10-index

Citations

Citations per year for David M. Goldenberg1972: 1 citations1973: 1 citations1974: 4 citations1975: 1 citations1976: 2 citations1977: 1 citations1978: 6 citations1979: 4 citations1980: 14 citations1981: 16 citations1982: 19 citations1983: 24 citations1984: 23 citations1985: 18 citations1986: 11 citations1987: 9 citations1988: 1 citations1989: 10 citations1990: 7 citations1991: 11 citations1992: 5 citations1993: 16 citations1994: 14 citations1995: 18 citations1996: 18 citations1997: 17 citations1998: 24 citations1999: 43 citations2000: 34 citations2001: 46 citations2002: 64 citations2003: 83 citations2004: 72 citations2005: 144 citations2006: 120 citations2007: 189 citations2008: 156 citations2009: 130 citations2010: 197 citations2011: 180 citations2012: 166 citations2013: 184 citations2014: 102 citations2015: 201 citations2016: 119 citations2017: 157 citations2018: 114 citations2019: 551 citations2020: 605 citations2021: 798 citations2022: 784 citations2023: 721 citations2024: 1,108 citations2025: 537 citations2026: 7 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,927 citing papers, 29.4% of this breakdownChina: 684 citing papers, 10.5% of this breakdownGermany: 415 citing papers, 6.3% of this breakdownItaly: 337 citing papers, 5.2% of this breakdownUnited Kingdom: 325 citing papers, 5% of this breakdownFrance: 298 citing papers, 4.6% of this breakdownNetherlands: 198 citing papers, 3% of this breakdownCanada: 184 citing papers, 2.8% of this breakdownSpain: 168 citing papers, 2.6% of this breakdownJapan: 158 citing papers, 2.4% of this breakdownSwitzerland: 153 citing papers, 2.3% of this breakdownAustralia: 139 citing papers, 2.1% of this breakdown
0%29.4%Other 23.8%

Institutions

Fields

  • Medicine72%
  • Biochemistry, Genetics and Molecular Biology13.8%
  • Immunology and Microbiology5.2%
  • Engineering3.1%
  • Materials Science1.7%
  • Chemistry1.2%
  • Other3%

Topics

  • Monoclonal and Polyclonal Antibodies Research9.5%
  • HER2/EGFR in Cancer Research7.3%
  • Radiopharmaceutical Chemistry and Applications5.6%
  • CAR-T cell therapy research3.5%
  • Advanced Breast Cancer Therapies2.5%
  • Cancer Immunotherapy and Biomarkers2.2%
  • Other69.4%

Coauthors

All papers

Open in search
  1. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Authors: Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo - New England Journal of Medicine 2021 cited by 1,543

  2. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

    Authors: Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan, Robert Iannone, Sarah A. Washkowitz, Robert M. Sharkey, William A. Wegener, Kevin Kalinsky - New England Journal of Medicine 2019 cited by 850

  3. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

    Authors: Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio, Jordan Berlin, Linda T. Vahdat, Gregory A. Masters, R Moroose, Alessandro D. Santin, Kevin Kalinsky, Vincent J. Picozzi, Joyce O’Shaughnessy, Jhanelle E. Gray, Takefumi Komiya, Joshua M. Lang, Jenny C. Chang, Alexander Starodub, David M. Goldenberg, Robert M. Sharkey, Pius Maliakal, Q. Hong, William A. Wegener, Trishna Goswami, Allyson J. Ocean - Annals of Oncology 2021 cited by 375

  4. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

    Authors: David M. Goldenberg, Thomas M. Cardillo, Serengulam V. Govindan, Edmund A. Rossi, Robert M. Sharkey - Oncotarget 2015 cited by 474

  5. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

    Authors: Aditya Bardia, Sara M. Tolaney, Kevin Punie, Delphine Loirat, Mafalda Oliveira, Kevin Kalinsky, Amelia Zelnak, Philippe Aftimos, Florence Dalenc, Sagar Sardesai, Erika Hamilton, Priyanka Sharma, Sabela Recalde, Eva Ciruelos Gil, T Traina, Joyce O’Shaughnessy, Javier Cortés, Mu‐Hung Tsai, Linda T. Vahdat, Véronique Dièras, Lisa A. Carey, Hope S. Rugo, David M. Goldenberg, Q. Hong, Martin Olivo, Loretta M. Itri, Sara A. Hurvitz - Annals of Oncology 2021 cited by 299

  6. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

    Authors: David M. Goldenberg, Rhona Stein, Robert M. Sharkey - Oncotarget 2018 cited by 312

  7. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

    Authors: Alexander Starodub, Allyson J. Ocean, Manish A. Shah, Michael J. Guarino, Vincent J. Picozzi, Linda T. Vahdat, Sajeve Thomas, Serengulam V. Govindan, Pius Maliakal, William A. Wegener, Steven A. Hamburger, Robert M. Sharkey, David M. Goldenberg - Clinical Cancer Research 2015 cited by 344

  8. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

    Authors: Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond, Rebecca Moroose, Steven J. Isakoff, Alexander Starodub, Nikita Shah, Joyce O’Shaughnessy, Kevin Kalinsky, Michael J. Guarino, Vandana G. Abramson, Dejan Juric, Sara M. Tolaney, Jordan Berlin, Wells A. Messersmith, Allyson J. Ocean, William A. Wegener, Pius Maliakal, Robert M. Sharkey, Serengulam V. Govindan, David M. Goldenberg, Linda T. Vahdat - Journal of Clinical Oncology 2017 cited by 409

  9. Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

    Authors: Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey, Preeti Trisal, David M. Goldenberg - Clinical Cancer Research 2011 cited by 300

  10. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

    Authors: Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey, Preeti Trisal, Roberto Arrojo, Donglin Liu, Edmund A. Rossi, Chien‐Hsing Chang, David M. Goldenberg - Bioconjugate Chemistry 2015 cited by 296

  11. Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

    Authors: Allyson J. Ocean, Alexander Starodub, Aditya Bardia, Linda T. Vahdat, Steven J. Isakoff, Michael J. Guarino, Wells A. Messersmith, Vincent J. Picozzi, Ingrid A. Mayer, William A. Wegener, Pius Maliakal, Serengulam V. Govindan, Robert M. Sharkey, David M. Goldenberg - Cancer 2017 cited by 236

  12. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

    Authors: Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Dièras, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky - npj Breast Cancer 2022 cited by 103

  13. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan

    Authors: David M. Goldenberg, Robert M. Sharkey - mAbs 2019 cited by 152

  14. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

    Authors: Kevin Kalinsky, Jennifer R. Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric, Joyce O’Shaughnessy, R Moroose, IA Mayer, Vandana G. Abramson, David M. Goldenberg, Robert M. Sharkey, Pius Maliakal, Q. Hong, Trishna Goswami, William A. Wegener, Aditya Bardia - Annals of Oncology 2020 cited by 145

  15. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy

    Authors: David M. Goldenberg, Robert M. Sharkey - Expert Opinion on Biological Therapy 2020 cited by 126

  16. A Review of Tissue Substitutes for Ultrasound Imaging

    Authors: Martin O. Culjat, David M. Goldenberg, Priyamvada Tewari, Rahul Singh - Ultrasound in Medicine & Biology 2010 cited by 650

  17. Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

    Authors: Rebecca S. Heist, Michael J. Guarino, Gregory A. Masters, W. Thomas Purcell, Alexander Starodub, Leora Horn, Ronald Scheff, Aditya Bardia, Wells A. Messersmith, Jordan Berlin, Allyson J. Ocean, Serengulam V. Govindan, Pius Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg, D. Ross Camidge - Journal of Clinical Oncology 2017 cited by 190

  18. Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer

    Authors: Melissa R. Junttila, Weiguang Mao, Xi Wang, Bu-Er Wang, Thinh Pham, John A. Flygare, Shang‐Fan Yu, Sharon Yee, David M. Goldenberg, Carter T. Fields, Jeffrey Eastham‐Anderson, Mallika Singh, Rajesh Vij, Jo-Anne Hongo, Ron Firestein, Melissa M. Schutten, Kelly M. Flagella, Paul Polakis, Andrew G. Polson - Science Translational Medicine 2015 cited by 186

  19. Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)

    Authors: Robert M. Sharkey, William J. McBride, Thomas M. Cardillo, Serengulam V. Govindan, Yang Wang, Edmund A. Rossi, Chien‐Hsing Chang, David M. Goldenberg - Clinical Cancer Research 2015 cited by 166

  20. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

    Authors: Jhanelle E. Gray, Rebecca S. Heist, Alexander Starodub, D. Ross Camidge, Ebenezer A. Kio, Gregory A. Masters, W. Thomas Purcell, Michael J. Guarino, Jamal Misleh, Charles Schneider, Bryan J. Schneider, Allyson J. Ocean, Tirrell Johnson, Leena Gandhi, Kevin Kalinsky, Ronald Scheff, Wells A. Messersmith, Serengulam V. Govindan, Pius Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg - Clinical Cancer Research 2017 cited by 159

  21. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers

    Authors: Rosalyn D. Blumenthal, Emmanuel John De Leon, Hans J. Hansen, David M. Goldenberg - BMC Cancer 2007 cited by 277

  22. Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy

    Authors: Sung-Ju Moon, Serengulam V. Govindan, Thomas M. Cardillo, Christopher D'Souza, Hans J. Hansen, David M. Goldenberg - Journal of Medicinal Chemistry 2008 cited by 159

  23. Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2 –wild-type Triple-Negative Breast Cancer

    Authors: Thomas M. Cardillo, Robert M. Sharkey, Diane L. Rossi, Roberto Arrojo, Ali Mostafa, David M. Goldenberg - Clinical Cancer Research 2017 cited by 127

  24. A Novel Method of 18F Radiolabeling for PET

    Authors: William J. McBride, Robert M. Sharkey, Habibe Karacay, Christopher D'Souza, Edmund A. Rossi, Peter Laverman, Chien‐Hsing Chang, Otto C. Boerman, David M. Goldenberg - Journal of Nuclear Medicine 2009 cited by 408